Skip to main content
Premium Trial:

Request an Annual Quote

KeyGene, Genalice Ink Licensing Deal

NEW YORK (GenomeWeb News) – Plant genomics firm KeyGene and startup bioinformatics company Genalice today announced a deal aimed at improving plant DNA analysis.

As part of the agreement, KeyGene will license Genalice MAP, a short-read alignment tool, which processes raw next-generation sequencing data into a small and easily manageable file for low-cost storage or further analysis.

"The breakthrough software solution … is a leap forward in improving our analysis pipeline and in staying ahead of competition," KeyGene CEO Arjen van Tunen said in a statement. "In addition, the strategic partnership with Genalice allows us to influence new functionalities within the product that will benefit our business."

Financial and other terms of the agreement were not disclosed.

Genalice is based in the Netherlands and launched late last year. Last month it said that it was awarded €200,000 ($275,000) for its participation in a European Union project to determine the causes of extreme aggressive behavior.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.